|Immunohistochemistry (Paraffin) (IHC (P))||1:50|
|Miscellaneous PubMed (MISC)||See 1 publications below|
|Tested Species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide derived from C-terminus of human FLT-1.|
|Purification||Antigen affinity chromatography|
|Storage buffer||PBS, pH 7.6, with 1% BSA|
|Contains||<0.1% sodium azide|
|Storage conditions||4° C, do not freeze|
Heat-mediated antigen retrieval is recommended prior to staining, using a 10mM citrate buffer, pH 6.0, for 10 minutes followed by cooling at room temperature for 20 min. Following antigen retrieval, incubate samples with primary antibody for 10 min at room temperature. A suggested positive control is placenta or angiosarcoma.
FLT-1/vascular endothelial growth factor receptor 1 (VEGFR1), a cell membrane receptor kinase, is a high affinity receptor for vascular endothelial growth factor and is putatively involved in the growth of endothelial cells and angiogenesis. It contains seven immunoglobulin like sequences in the extracellular domain and exhibits sequence similarity to FLK-1 and FLT-4.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: FLT; FLT-1; Fms-like tyrosine kinase 1; fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor); Tyrosine-protein kinase FRT; Tyrosine-protein kinase receptor FLT; Vascular endothelial growth factor receptor 1; Vascular permeability factor receptor; VEGFR-1; VEGFR1
Gene Aliases: FLT; FLT-1; FLT1; FRT; VEGFR-1; VEGFR1
UniProt ID: (Human) P17948
Entrez Gene ID: (Human) 2321
If an Invitrogen™ antibody doesn’t perform as described on our website or datasheet, we’ll replace the product at no cost to you, or provide you with a credit for a future purchase.*
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.